A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.

@article{Pancheri2002ADR,
  title={A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.},
  author={Paolo Pancheri and Pierluigi Scapicchio and Roberto Delle Chiaie},
  journal={The international journal of neuropsychopharmacology},
  year={2002},
  volume={5 4},
  pages={
          287-94
        }
}
S-adenosyl-L-methionine (SAMe) is a natural substance which constitutes the most important methyl donor in transmethylation reactions in the central nervous system. Several clinical trials have shown that SAMe possesses an antidepressant activity. This multicentre study was carried out to confirm both efficacy and safety of SAMe in the treatment of major depression. SAMe was given intramuscularly (i.m.) at a dose of 400 mg/d, double-blind, vs. 150 mg/d oral Imipramine (IMI) in patients with a… 

Figures and Tables from this paper

A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia

Evaluation of S-adenosyl l-methionine in a double-blinded, randomized, placebo-controlled, clinical trial for treatment of presumptive osteoarthritis in the dog.

Data do not support the use of SAMe as an effective stand alone treatment for reducing clinical signs of OA, as measured by PVF, VI, goniometry, CBPI (both Severity and Impact), and examination score within 6 weeks of treatment.

S-Adenosyl-L-Methionine for Major Depressive Disorder

It is suggested that SAMe may have therapeutic potential in treating major depressive disorder and may offer considerable advantages as an alternative to antidepressant drugs or as an adjunctive therapy in the treatment of MDD and/or treatment-resistant depression (TRD).

A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.

Overall, SAMe is a well-tolerated medication, which may offer considerable advantages as an alternative to antidepressant drugs or as an add-on therapy in the treatment of MDD and TRD.

S-adenosyl-methionine in depression: A comprehensive review of the literature

The authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use ofSAMe for the treatment ofMDD, and proposes a model that would explain the actions of SAMi in the central nervous system.

S-adenosyl methionine (SAMe) for depression in adults.

Low quality evidence that SAMe is superior to placebo as add-on to SSRIs in terms of change in depressive symptoms was found, and the risk of selection, performance, detection and attrition bias was judged as unclear or low, and one study was at high risk of attrition bias.

SAMe use in children and adolescents

S-adenosylmethionine (SAMe) is an agent that is indigenous to the body, and may offer another choice for treatment-resistant Major Depression in children and adolescents, and has a fairly rapid onset of action.

References

SHOWING 1-10 OF 48 REFERENCES

Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women.

There was a significantly greater improvement in depressive symptoms in the group treated with SAMe compared to the placebo group from day 10 of the study, and side effects were mild and transient.

Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial.

The results suggest that oral S-adenosylmethionine is a safe, effective antidepressant with few side effects and a rapid onset of action, and support a role for methylation in the pathophysiology of depression.

S-adenosylmethionine treatment of depression: a controlled clinical trial.

The antidepressant properties of S-adenosylmethionine, an endogenous methyl donor, were studied in inpatients who met the DSM-III criteria for major depression and produced superior results by the end of the first week of treatment.

Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study

  • L. Gram
  • Psychology, Medicine
    Psychopharmacology
  • 2004
Citalopram was devoid of the typical autonomic side effects and orthostatic hypotension seen with clomipramine and seemed to be related in particular to the sleep items, but other items covering depression, retardation and anxiety/agitation also contributed to the difference in total score.

S‐adenosylmethionine blood levels in major depression: changes with drug treatment

The significant correlation between plasma SAMe levels and the degree of clinical improvement in depressed patients regardless of the type of treatment suggests that SAMe may play an important role in regulating mood.

Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression

A role for brain polyamines in depression and in reward processes is suggested and it is suggested that the antidepressant effect of SAMe may be due, at least in part, to a normalization of putrescine levels in the nucleus accumbens septi.

S‐adenosyl‐l‐methionine (SAMe) as antidepressant: meta‐analysis of clinical studies

  • G. Bressa
  • Psychology, Medicine
    Acta neurologica Scandinavica. Supplementum
  • 1994
The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.

Influence of S‐adenosyl‐L‐methionine on chronic mild stress‐induced anhedonia in castrated rats

Results show that SAMe reverses an experimental condition of ‘depression‐like’ behaviour in rats, the effect being more rapid and complete than that of imipramine, and without apparent side effects.